Sphingosine 1-phosphate receptor 3–deficient dendritic cells modulate splenic responses to ischemia-reperfusion injury

Amandeep Bajwa, Liping Huang, Elvira Kurmaeva, Joseph C. Gigliotti, Hong Ye, Jacqueline Miller, Diane L. Rosin, Peter I. Lobo, Mark D. Okusa

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The plasticity of dendritic cells (DCs) permits phenotypic modulation ex vivo by gene expression or pharmacologic agents, and these modified DCs can exert therapeutic immunosuppressive effects in vivo through direct interactions with T cells, either inducing T regulatory cells (T REG s) or causing anergy. Sphingosine 1-phosphate (S1P) is a sphingolipid and the natural ligand for five G protein–coupled receptors (S1P1, S1P2, S1P3, S1P4, and S1P5), and S1PR agonists reduce kidney ischemia-reperfusion injury (IRI) in mice. S1pr3 2 / 2 mice are protected from kidney IRI, because DCs do not mature. We tested the therapeutic advantage of S1pr3 2 / 2 bone marrow–derived dendritic cell (BMDC) transfers in kidney IRI. IRI produced a rise in plasma creatinine (PCr) levels in mice receiving no cells (NCs) and mice pretreated with wild-type (WT) BMDCs. However, S1pr3 2 / 2 BMDC–pretreated mice were protected from kidney IRI. S1pr3 2 /2 BMDC–pretreated mice had significantly higher numbers of splenic T REG s compared with NC and WT BMDC–pretreated mice. S1pr3 2 / 2 BMDCs did not attenuate IRI in splenectomized, Rag-1 2 / 2 , or CD11c + DC–depleted mice. Additionally, S1pr3 2 / 2 BMDC–dependent protection required CD169 + marginal zone macrophages and the macrophage–derived chemokine CCL22 to increase splenic CD4 + Foxp3 + T REG s. Pretreatment with S1pr3 2 / 2 BMDCs also induced T REG -dependent protection against IRI in an allogeneic mouse model. In summary, adoptively transferred S1pr3 2 / 2 BMDCs prevent kidney IRI through interactions within the spleen and expansion of splenic CD4 + Foxp3 + T REG s. We conclude that genetically induced deficiency of S1pr3 in allogenic BMDCs could serve as a therapeutic approach to prevent IRI-induced AKI.

Original languageEnglish (US)
Pages (from-to)1076-1090
Number of pages15
JournalJournal of the American Society of Nephrology
Volume27
Issue number4
DOIs
StatePublished - Jan 1 2016

Fingerprint

Lysosphingolipid Receptors
Reperfusion Injury
Dendritic Cells
Regulatory T-Lymphocytes
Kidney
Chemokine CCL22
Sphingolipids
Therapeutic Uses
Immunosuppressive Agents
Creatinine
Spleen
Macrophages
Ligands
T-Lymphocytes
Gene Expression
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Sphingosine 1-phosphate receptor 3–deficient dendritic cells modulate splenic responses to ischemia-reperfusion injury. / Bajwa, Amandeep; Huang, Liping; Kurmaeva, Elvira; Gigliotti, Joseph C.; Ye, Hong; Miller, Jacqueline; Rosin, Diane L.; Lobo, Peter I.; Okusa, Mark D.

In: Journal of the American Society of Nephrology, Vol. 27, No. 4, 01.01.2016, p. 1076-1090.

Research output: Contribution to journalArticle

Bajwa, Amandeep ; Huang, Liping ; Kurmaeva, Elvira ; Gigliotti, Joseph C. ; Ye, Hong ; Miller, Jacqueline ; Rosin, Diane L. ; Lobo, Peter I. ; Okusa, Mark D. / Sphingosine 1-phosphate receptor 3–deficient dendritic cells modulate splenic responses to ischemia-reperfusion injury. In: Journal of the American Society of Nephrology. 2016 ; Vol. 27, No. 4. pp. 1076-1090.
@article{a94c7e445292421fa2ea3057b39defec,
title = "Sphingosine 1-phosphate receptor 3–deficient dendritic cells modulate splenic responses to ischemia-reperfusion injury",
abstract = "The plasticity of dendritic cells (DCs) permits phenotypic modulation ex vivo by gene expression or pharmacologic agents, and these modified DCs can exert therapeutic immunosuppressive effects in vivo through direct interactions with T cells, either inducing T regulatory cells (T REG s) or causing anergy. Sphingosine 1-phosphate (S1P) is a sphingolipid and the natural ligand for five G protein–coupled receptors (S1P1, S1P2, S1P3, S1P4, and S1P5), and S1PR agonists reduce kidney ischemia-reperfusion injury (IRI) in mice. S1pr3 2 / 2 mice are protected from kidney IRI, because DCs do not mature. We tested the therapeutic advantage of S1pr3 2 / 2 bone marrow–derived dendritic cell (BMDC) transfers in kidney IRI. IRI produced a rise in plasma creatinine (PCr) levels in mice receiving no cells (NCs) and mice pretreated with wild-type (WT) BMDCs. However, S1pr3 2 / 2 BMDC–pretreated mice were protected from kidney IRI. S1pr3 2 /2 BMDC–pretreated mice had significantly higher numbers of splenic T REG s compared with NC and WT BMDC–pretreated mice. S1pr3 2 / 2 BMDCs did not attenuate IRI in splenectomized, Rag-1 2 / 2 , or CD11c + DC–depleted mice. Additionally, S1pr3 2 / 2 BMDC–dependent protection required CD169 + marginal zone macrophages and the macrophage–derived chemokine CCL22 to increase splenic CD4 + Foxp3 + T REG s. Pretreatment with S1pr3 2 / 2 BMDCs also induced T REG -dependent protection against IRI in an allogeneic mouse model. In summary, adoptively transferred S1pr3 2 / 2 BMDCs prevent kidney IRI through interactions within the spleen and expansion of splenic CD4 + Foxp3 + T REG s. We conclude that genetically induced deficiency of S1pr3 in allogenic BMDCs could serve as a therapeutic approach to prevent IRI-induced AKI.",
author = "Amandeep Bajwa and Liping Huang and Elvira Kurmaeva and Gigliotti, {Joseph C.} and Hong Ye and Jacqueline Miller and Rosin, {Diane L.} and Lobo, {Peter I.} and Okusa, {Mark D.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1681/ASN.2015010095",
language = "English (US)",
volume = "27",
pages = "1076--1090",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "4",

}

TY - JOUR

T1 - Sphingosine 1-phosphate receptor 3–deficient dendritic cells modulate splenic responses to ischemia-reperfusion injury

AU - Bajwa, Amandeep

AU - Huang, Liping

AU - Kurmaeva, Elvira

AU - Gigliotti, Joseph C.

AU - Ye, Hong

AU - Miller, Jacqueline

AU - Rosin, Diane L.

AU - Lobo, Peter I.

AU - Okusa, Mark D.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The plasticity of dendritic cells (DCs) permits phenotypic modulation ex vivo by gene expression or pharmacologic agents, and these modified DCs can exert therapeutic immunosuppressive effects in vivo through direct interactions with T cells, either inducing T regulatory cells (T REG s) or causing anergy. Sphingosine 1-phosphate (S1P) is a sphingolipid and the natural ligand for five G protein–coupled receptors (S1P1, S1P2, S1P3, S1P4, and S1P5), and S1PR agonists reduce kidney ischemia-reperfusion injury (IRI) in mice. S1pr3 2 / 2 mice are protected from kidney IRI, because DCs do not mature. We tested the therapeutic advantage of S1pr3 2 / 2 bone marrow–derived dendritic cell (BMDC) transfers in kidney IRI. IRI produced a rise in plasma creatinine (PCr) levels in mice receiving no cells (NCs) and mice pretreated with wild-type (WT) BMDCs. However, S1pr3 2 / 2 BMDC–pretreated mice were protected from kidney IRI. S1pr3 2 /2 BMDC–pretreated mice had significantly higher numbers of splenic T REG s compared with NC and WT BMDC–pretreated mice. S1pr3 2 / 2 BMDCs did not attenuate IRI in splenectomized, Rag-1 2 / 2 , or CD11c + DC–depleted mice. Additionally, S1pr3 2 / 2 BMDC–dependent protection required CD169 + marginal zone macrophages and the macrophage–derived chemokine CCL22 to increase splenic CD4 + Foxp3 + T REG s. Pretreatment with S1pr3 2 / 2 BMDCs also induced T REG -dependent protection against IRI in an allogeneic mouse model. In summary, adoptively transferred S1pr3 2 / 2 BMDCs prevent kidney IRI through interactions within the spleen and expansion of splenic CD4 + Foxp3 + T REG s. We conclude that genetically induced deficiency of S1pr3 in allogenic BMDCs could serve as a therapeutic approach to prevent IRI-induced AKI.

AB - The plasticity of dendritic cells (DCs) permits phenotypic modulation ex vivo by gene expression or pharmacologic agents, and these modified DCs can exert therapeutic immunosuppressive effects in vivo through direct interactions with T cells, either inducing T regulatory cells (T REG s) or causing anergy. Sphingosine 1-phosphate (S1P) is a sphingolipid and the natural ligand for five G protein–coupled receptors (S1P1, S1P2, S1P3, S1P4, and S1P5), and S1PR agonists reduce kidney ischemia-reperfusion injury (IRI) in mice. S1pr3 2 / 2 mice are protected from kidney IRI, because DCs do not mature. We tested the therapeutic advantage of S1pr3 2 / 2 bone marrow–derived dendritic cell (BMDC) transfers in kidney IRI. IRI produced a rise in plasma creatinine (PCr) levels in mice receiving no cells (NCs) and mice pretreated with wild-type (WT) BMDCs. However, S1pr3 2 / 2 BMDC–pretreated mice were protected from kidney IRI. S1pr3 2 /2 BMDC–pretreated mice had significantly higher numbers of splenic T REG s compared with NC and WT BMDC–pretreated mice. S1pr3 2 / 2 BMDCs did not attenuate IRI in splenectomized, Rag-1 2 / 2 , or CD11c + DC–depleted mice. Additionally, S1pr3 2 / 2 BMDC–dependent protection required CD169 + marginal zone macrophages and the macrophage–derived chemokine CCL22 to increase splenic CD4 + Foxp3 + T REG s. Pretreatment with S1pr3 2 / 2 BMDCs also induced T REG -dependent protection against IRI in an allogeneic mouse model. In summary, adoptively transferred S1pr3 2 / 2 BMDCs prevent kidney IRI through interactions within the spleen and expansion of splenic CD4 + Foxp3 + T REG s. We conclude that genetically induced deficiency of S1pr3 in allogenic BMDCs could serve as a therapeutic approach to prevent IRI-induced AKI.

UR - http://www.scopus.com/inward/record.url?scp=85017065120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017065120&partnerID=8YFLogxK

U2 - 10.1681/ASN.2015010095

DO - 10.1681/ASN.2015010095

M3 - Article

C2 - 26286732

AN - SCOPUS:85017065120

VL - 27

SP - 1076

EP - 1090

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 4

ER -